LEXX (Lexaria Bioscience) Earnings per share growth rate in current year
The current EPS YoY growth rate demonstrates earnings per share dynamics, with the 0.00 value serving as the baseline metric for Lexaria Bioscience (LEXX). The DehydraTECH B2B licensing model attracts new partners due to its efficiency in the GLP-1 segment. Production is fully outsourced to contract manufacturing organizations (CMO), creating a strong operational dependency. The proprietary method accelerates substance absorption, reducing both dosage and side effects.
Comprehensive metric breakdowns and analytics for lexariabioscience.com (LEXX)
- stock price and consensus target price:
- business market valuation indicators:
- balance sheet equity data:
- debt and liquidity details:
Debt to Capital Lexaria Bioscience|LEXX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Ratio Lexaria Bioscience Corp.|LEXX - Company Aggregate Debts|Debts to Book Capitalization Lexaria Bioscience Corp.|LEXX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Lexaria Bioscience|Interim Coverage Ratio lexariabioscience.com
- net income and valuation multiples indicators:
LEXX - Net Profit|Projected Future Earnings Lexaria Bioscience|LEXX - Price to Earnings Ratio|Future Price to Earnings Multiple Lexaria Bioscience Corp.|LEXX - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexaria Bioscience Corp.|LEXX - Operating profit EBITDA|Net earnings per share for the last four quarters Lexaria Bioscience|LEXX - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months lexariabioscience.com|LEXX - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Lexaria Bioscience
Fundamental valuation:Lexaria Bioscience
Lexaria Bioscience focuses on monetizing its innovative DehydraTECH system through strategic licensing. Earnings per share dynamics reflect the efficiency of this model, comparing current financial results with the same period last year. This indicator measures the speed of business scaling and its transition toward maturity. The narrowing amplitude of fluctuations in the 12-month earnings per share growth rate signals a stabilization of market expectations. The deceleration of this growth warns investors of the risk of capital freezing.
Main competitors
Haleon PLC - Earnings per share increase in current year|KVUE (Kenvue Corp) - Earnings growth in current year|Earnings per share growth rate in current year Verona Pharma Inc. VRNA|Earnings per share growth in current year Jyong Biotech Ltd (MENS)|LGND (ligand.com) - Earnings per share increase in current year|Earnings per share growth in current year Amneal AMRX|Perrigo Company PLC - Earnings per share growth in current year|Alvotech Corp - Earnings growth in current year|Earnings per share growth rate in current year Liquidia Inc.|GLPG (Galapagos NV) - Net earnings per share growth this year|Earnings per share growth this year ANIP|MNKD (MannKind) - Earnings growth in current year|Earnings growth in current year Amphastar Pharmaceuticals Inc|Earnings per share growth in current year Pacira (PCRX)|SPRY (ARS Corp) - Earnings per share increase in current year|Earnings growth in current year TBPH (Theravance Biopharma)|Expected net earnings per share growth this year aquestive.com (AQST)|scPharma - Earnings growth in current year|TECX - Earnings growth in current year|TNXP (Tonix Pharmaceuticals Inc.) - Net earnings per share growth this year|China SXT Pharmaceuticals, Inc. - Earnings per share increase in current year|EPRX (Eupraxia Pharmaceuticals, Inc.) - Earnings growth in current year|Earnings per share growth in current year BHST|Earnings growth in current year EXOZ|Expected net earnings per share growth this year oramed.com|Earnings per share growth in current year Entera Bio ENTX|MindWalk Therapeutics (HYFT) - Earnings per share growth rate in current year|ABVC - Earnings per share growth in current year|Expected net earnings per share growth this year cumberlandpharma.com CPIX|QNTM: Earnings growth in current year|Net earnings per share growth this year FibroGen Inc|TELO (Telomir Pharma) - Earnings growth in current year|Rani Therapeutics Inc (RANI) - Expected net earnings per share growth this year|Earnings growth in current year SNYR|RLYB - Earnings per share growth rate in current year|Earnings per share growth in current year Pulmatrix PULM|PTHL: Earnings per share growth this year|Aptorum - Earnings growth in current year|Lyra Therapeutics Inc (LYRA) - Net earnings per share growth this year|IBO: Earnings growth in current year|Earnings per share growth rate in current year TNF Pharmaceuticals, Inc. (TNFA)|Earnings per share growth in current year cbdMD Inc.|Earnings per share growth in current year PRFX|Earnings growth in current year CYTO|LIPO - Earnings per share growth rate in current year|OptiNose, Inc. - Net earnings per share growth this year|PIRS: Earnings per share growth this year|PROC: Net earnings per share growth this year|PTPI (Petros Pharmaceuticals Inc) - Earnings per share growth this year|Qilian International Holding Group Limited (QLI) - Earnings per share growth in current year|Earnings per share trend in current year SLRN (ACELYRIN Inc.)|TFFP (TFF Pharmaceuticals) - Earnings growth in current year
